Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock


Single-cell transcriptome sequencing reveals the immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine.


The BBIBP-CorV severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inactivated vaccine has been authorized for emergency use and widely distributed. We used single-cell transcriptome sequencing to characterize the dynamics of immune responses to the BBIBP-CorV inactivated vaccine. In addition to the expected induction of humoral immunity, we found that the inactivated vaccine induced multiple, comprehensive immune responses, including significantly increased proportions of CD16+ monocytes and activation of monocyte antigen presentation pathways; T-cell activation pathway upregulation in CD8+ T cells, along with increased activation of CD4+ T cells; significant enhancement of cell-cell communications between innate and adaptive immunity; and the induction of regulatory CD4+ T cells and co-inhibitory interactions to maintain immune homeostasis after vaccination. Additionally, comparative analysis revealed higher neutralizing antibody levels, distinct expansion of naive T cells, a shared increased proportion of regulatory CD4+ T cells, and upregulated expression of functional genes in booster dose recipients with a longer interval after the second vaccination. Our research will support a comprehensive understanding of the systemic immune responses elicited by the BBIBP-CorV inactivated vaccine, which will facilitate the formulation of better vaccination strategies and the design of new vaccines.

Authors: Yin J, Zhao Y, Huang F, Yang Y, Huang Y, Zhuang Z, Wang Y, Wang Z, Lin X, Zheng Y, Zhou W, Wang S, Xu Z, Ye B, Guo Y, Lei W, Li L, Tian J, Gan J, Wang H, Wang W, Ma P, Liu C, Wei X, Shi X, Wang Z, Wang Y, Liu Y, Yang M, Yuan Y, Song Y, Ma W, Huang Z, Liu
Journal: Innovation (Camb);2023 Jan 30;4(1):100359. . doi:10.1016/j.xinn.2022.100359
Year: 2023
PubMed: PMID: 36506806 (Go to PubMed)